JPMorgan Chase & Co. Sells 17,665 Shares of 2seventy bio, Inc. (NASDAQ:TSVT)

JPMorgan Chase & Co. trimmed its position in 2seventy bio, Inc. (NASDAQ:TSVT) by 3.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 514,767 shares of the company’s stock after selling 17,665 shares during the period. JPMorgan Chase & Co. owned approximately 1.00% of 2seventy bio worth $2,430,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. BBR Partners LLC lifted its holdings in shares of 2seventy bio by 620.0% in the third quarter. BBR Partners LLC now owns 180,000 shares of the company’s stock valued at $850,000 after purchasing an additional 155,000 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of 2seventy bio by 1.1% in the third quarter. Geode Capital Management LLC now owns 1,176,244 shares of the company’s stock valued at $5,553,000 after purchasing an additional 13,144 shares in the last quarter. GSA Capital Partners LLP bought a new stake in 2seventy bio during the third quarter worth about $64,000. FMR LLC raised its holdings in 2seventy bio by 22.0% during the third quarter. FMR LLC now owns 148,545 shares of the company’s stock worth $701,000 after acquiring an additional 26,738 shares in the last quarter. Finally, XTX Topco Ltd raised its holdings in 2seventy bio by 61.1% during the third quarter. XTX Topco Ltd now owns 24,416 shares of the company’s stock worth $115,000 after acquiring an additional 9,257 shares in the last quarter. 93.90% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of 2seventy bio in a report on Saturday. One research analyst has rated the stock with a sell rating, three have issued a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, 2seventy bio presently has a consensus rating of “Moderate Buy” and an average price target of $9.00.

2seventy bio Stock Down 6.1 %

Shares of NASDAQ TSVT opened at $2.45 on Wednesday. The business’s 50 day moving average price is $3.24 and its two-hundred day moving average price is $4.14. The company has a market cap of $126.40 million, a PE ratio of -1.32 and a beta of 1.76. 2seventy bio, Inc. has a twelve month low of $2.35 and a twelve month high of $6.40.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.